Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply
- PMID: 31021372
- DOI: 10.1001/jamaoncol.2019.0650
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply
Comment on
-
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.JAMA Oncol. 2019 Jan 1;5(1):30-36. doi: 10.1001/jamaoncol.2018.4070. JAMA Oncol. 2019. PMID: 30267080 Free PMC article.
-
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.JAMA Oncol. 2019 Jun 1;5(6):915-916. doi: 10.1001/jamaoncol.2019.0647. JAMA Oncol. 2019. PMID: 31021371 No abstract available.
-
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.JAMA Oncol. 2019 Jun 1;5(6):915. doi: 10.1001/jamaoncol.2019.0644. JAMA Oncol. 2019. PMID: 31021388 No abstract available.
-
Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.JAMA Oncol. 2019 Jun 1;5(6):914-915. doi: 10.1001/jamaoncol.2019.0641. JAMA Oncol. 2019. PMID: 31021391 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
